朴雪品牌怎么样 申请店铺

我要投票 朴雪在补铁锌硒行业中的票数:776 更新时间:2026-02-07
朴雪是哪个国家的品牌?「朴雪」是 哈药集团有限公司 旗下著名品牌。该品牌发源于黑龙江,由创始人徐志越在1989期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力朴雪品牌出海!将品牌入驻外推网,定制朴雪品牌推广信息,可以显著提高朴雪产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

朴雪怎么样

朴雪为哈药集团制药六厂旗下保健食品品牌,主要产品为朴雪乳酸亚铁口服液,适用于营养性贫血者,能有效改善营养性贫血。

哈药六厂是以生产化学药品及中成药为主,保健食品和"纯中纯"无菌纯净水系列、茶饮料系列为辅的综合制药企业,制剂手段完备,设备先进,可生产大容量注射剂、口服液、糖浆剂、片剂、胶囊剂、颗粒剂和原料药等,产品远销全国。主导产品:盖中盖系列保健食品、严迪、泻痢停、为消、护彤、丹王颗粒等畅销产品。1999年企业开始跨入保健食品生产企业行列。

哈药集团制药六厂(以下简称为“哈药六厂”)始建于1977年,1995年改制为国有控股的股份制企业,2006年改制为国有控股、中外合资企业,是以生产化学药品为主、以保健食品和饮品为辅的综合性企业。

建厂以后,企业长期处于低速发展状态,由于连年亏损,已濒临破产的边缘。1988年以后,全厂职工在调整后的厂级领导班子的正确领导下,团结协作,艰苦奋斗,在短短的二十多年的时间里使企业产生了裂变式的、超常规的发展,取得了令人瞩目的成绩,现已成为省、市政府的纳税大户和哈药集团的四大骨干企业之一,连续多年完成集团公司下达的各项经济技术指标。厂区占地为10万平方米,建筑面积达25万平方米。

企业生产设备先进完善,按照GMP标准要求,全面系统地改造了综合制剂生产车间、固体制剂生产车间及饮品综合生产车间,并全面通过GMP认证和相关验收。

药品生产剂型包括:原料药(人工牛黄)、片剂、胶囊剂、颗粒剂、口服液、糖浆剂、口服溶液剂、合剂(含中药提取);橡胶膏剂、膏药、软胶囊剂和巴布剂12个剂型170余种产品。

保健食品生产包括片剂、口服液两个剂型14种产品。

饮品生产包括饮用纯净水、茶饮料、果汁系列等11种产品。

主导产品有严迪牌罗红霉素分散片、护彤牌小儿氨酚黄那敏颗粒、泻利停牌颠茄磺苄啶片、为消牌乳酸菌素片、新盖中盖牌高钙片、哈药六牌钙加锌口服液、朴雪乳酸亚铁口服液、新盖中盖牌乳酸钙口服液及纯中纯系列饮品等。

Park snow is a brand of health food under the sixth pharmaceutical factory of Harbin Pharmaceutical Group. Its main product is park snow ferrous lactate oral liquid, which is suitable for the patients with nutritional anemia and can effectively improve nutritional anemia. Harbin No.6 Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise mainly engaged in the production of chemicals and Chinese patent medicines, supplemented by health food and "pure and medium" aseptic pure water series and tea beverage series. With complete preparation means and advanced equipment, it can produce large volume injections, oral liquids, syrups, tablets, capsules, granules and APIs. Its products are sold all over the country. Leading products: gaizhonggai series of health food, Yandi, XIELITING, Weixiao, Hutong, Danwang granules and other best-selling products. In 1999, enterprises began to enter the ranks of health food production enterprises. Harbin Pharmaceutical Group Pharmaceutical No.6 factory (hereinafter referred to as "Harbin Pharmaceutical No.6 factory") was founded in 1977, restructured into a state-owned holding joint-stock enterprise in 1995 and a state-owned holding and Sino foreign joint venture in 2006. It is a comprehensive enterprise mainly engaged in the production of chemicals, supplemented by health food and drinks. After the establishment of the factory, the enterprise has been in a state of low-speed development for a long time. Because of years of losses, it is on the verge of bankruptcy. After 1988, under the correct leadership of the adjusted leading group at the factory level, the employees of the whole plant united and cooperated with each other and worked hard. In a short period of more than 20 years, the enterprise had a fission and unconventional development, and made remarkable achievements. Now it has become one of the four backbone enterprises of the provincial and municipal governments and Harbin Pharmaceutical Group, and has completed the group's corporate governance for many years in a row Economic and technical indicators issued by the division. The factory covers an area of 100000 square meters, with a building area of 250000 square meters. The production equipment of the enterprise is advanced and perfect. According to the requirements of GMP standard, the comprehensive preparation production workshop, solid preparation production workshop and beverage comprehensive production workshop have been comprehensively and systematically reformed, and have passed GMP certification and relevant acceptance. Drug production dosage forms include: raw material drug (artificial bezoar), tablet, capsule, granule, oral liquid, syrup, oral solution, mixture (including extraction of traditional Chinese Medicine); rubber plaster, plaster, soft capsule and cataplasm 12 dosage forms of 170 kinds of products. The production of health food includes 14 kinds of products in two dosage forms: tablet and oral liquid. The beverage production includes 11 kinds of products such as drinking pure water, tea beverage, juice series, etc. The main products are Yandi brand roxithromycin dispersible tablets, Houtong brand Xiaoer aminophenol huangnamin granules, XIELITING brand belladonna sulfonylbenzylidine tablets, Weixiao brand Lactobacillin tablets, xingaizhonggai brand high calcium tablets, Harbin medicine Liupai calcium and zinc oral liquid, Puxue ferrous lactate oral liquid, xingaizhonggai brand calcium lactate oral liquid and pure medium pure series drinks, etc.

本文链接: https://brand.waitui.com/43a43fa04.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

央行等八部门:在境内开展现实世界资产代币化活动,应予以禁止

36氪获悉,中国人民银行等八部门发布关于进一步防范和处置虚拟货币等相关风险的通知。其中提到,现实世界资产代币化是指使用加密技术及分布式账本或类似技术,将资产的所有权、收益权等转化为代币(通证)或者具有代币(通证)特性的其他权益、债券凭证,并进行发行和交易的活动。在境内开展现实世界资产代币化活动,以及提供有关中介、信息技术服务等,涉嫌非法发售代币票券、擅自公开发行证券、非法经营证券期货业务、非法集资等非法金融活动,应予以禁止;经业务主管部门依法依规同意,依托特定金融基础设施开展的相关业务活动除外。境外单位和个人不得以任何形式非法向境内主体提供现实世界资产代币化相关服务。

59分钟前

央行等八部门:金融机构不得为虚拟货币相关业务活动提供账户开立、资金划转和清算结算等服务

36氪获悉,中国人民银行等八部门发布关于进一步防范和处置虚拟货币等相关风险的通知。其中提到,通知指出,强化对金融、中介、技术等服务机构的管理。金融机构(含非银行支付机构)不得为虚拟货币相关业务活动提供账户开立、资金划转和清算结算等服务,不得发行和销售虚拟货币相关金融产品,不得将虚拟货币及相关金融产品纳入抵质押品范围,不得开展与虚拟货币相关的保险业务或将虚拟货币纳入保险责任范围,并加强风险监测,发现违法违规问题线索应及时向相关部门报告。金融机构(含非银行支付机构)不得为未经同意的现实世界资产代币化相关业务以及相关金融产品提供托管、清算结算等服务。有关中介机构、信息技术服务机构不得为未经同意的现实世界资产代币化相关业务以及相关金融产品提供中介、技术等服务。

59分钟前

央行等八部门:任何单位和个人投资虚拟货币、现实世界资产代币及相关金融产品,损失由其自行承担

36氪获悉,中国人民银行等八部门发布关于进一步防范和处置虚拟货币等相关风险的通知。通知指出,违反本通知规定开展虚拟货币、现实世界资产代币化相关非法金融活动,以及为虚拟货币、现实世界资产代币化相关业务提供服务的,依照有关规定予以处罚;构成犯罪的,依法追究刑事责任。对于明知或应知境外主体非法向境内提供虚拟货币、现实世界资产代币化相关服务,仍为其提供协助的境内单位和个人,依法追究有关责任;构成犯罪的,依法追究刑事责任。任何单位和个人投资虚拟货币、现实世界资产代币及相关金融产品,违背公序良俗的,相关民事法律行为无效,由此引发的损失由其自行承担;涉嫌破坏金融秩序、危害金融安全的,由相关部门依法查处。

59分钟前

中国人民银行、中国证监会有关负责人就《关于进一步防范和处置虚拟货币等相关风险的通知》答记者问

36氪获悉,中国人民银行、中国证监会有关负责人就《关于进一步防范和处置虚拟货币等相关风险的通知》答记者问。关于虚拟货币,长期以来,境内始终对虚拟货币相关业务活动保持禁止性的政策立场。2013年,中国人民银行等五部门联合印发《关于防范比特币风险的通知》,明确比特币是一种特定的虚拟商品,不能且不应作为货币在市场上流通使用。2021年印发的《关于进一步防范和处置虚拟货币交易炒作风险的通知》进一步明确,比特币、以太币,以及泰达币等稳定币,均不具有与法定货币等同的法律地位,在境内开展虚拟货币相关业务活动属于非法金融活动,一律严格禁止。《通知》延续了近年来的政策立场,重申虚拟货币不具有与法定货币等同的法律地位,在境内开展虚拟货币相关业务活动属于非法金融活动,境外单位和个人不得以任何形式非法向境内主体提供虚拟货币相关服务。

59分钟前

分子之心MoleculeOS完成重大代际升级

36氪获悉,近日,分子之心宣布其AI蛋白质优化与设计平台MoleculeOS完成重大代际升级。同时,分子之心依托NewOrigin(达尔文)创新算法,解决了AlphaFold 3等模型无法解决的产业难题。

59分钟前

本页详细列出关于朴雪的品牌信息,含品牌所属公司介绍,朴雪所处行业的品牌地位及优势。
咨询